News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...
Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat ...
Objectives To determine the prevalence, patterns and correlates of medicinal herb use in a rural Iranian population and to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results